Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials

Ähnliche Einträge

• Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
  von: Michelle Look, et al.
  Veröffentlicht: (2025)
• Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
  von: Theresa Hunter Gibble, et al.
  Veröffentlicht: (2025)
• Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
  von: Alpana P. Shukla, et al.
  Veröffentlicht: (2025)
• Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight”
  Veröffentlicht: (2025)
• Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials
  von: Deborah B. Horn, et al.
  Veröffentlicht: (2025)